Related Experiment Video
Updated: Nov 23, 2025

Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
Mesenchymal Stem/Stromal Cells Increase Cardiac miR-187-3p Expression in a Polymicrobial Animal Model of Sepsis
Amin M Ektesabi1,2, Keisuke Mori2,3, James N Tsoporis2
1Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Abstract:
Sepsis-induced myocardial dysfunction (MD) is an important pathophysiological feature of multiorgan failure caused by a dysregulated host response to infection. Patients with MD continue to be managed in intensive care units with limited understanding of the molecular mechanisms controlling disease pathogenesis. Emerging evidences support the use of mesenchymal stem/stromal cell (MSC) therapy for treating critically ill septic patients. Combining this with the known role that microRNAs (miRNAs) play in reversing sepsis-induced myocardial-dysfunction, this study sought to investigate how MSC administration alters miRNA expression in the heart. Mice were randomized to experimental polymicrobial sepsis induced by cecal ligation and puncture (CLP) or sham surgery, treated with either MSCs (2.5 × 105) or placebo (saline). Twenty-eight hours post-intervention, RNA was collected from whole hearts for transcriptomic and microRNA profiling. The top microRNAs differentially regulated in hearts by CLP and MSC administration were used to generate a putative mRNA-miRNA interaction network. Key genes, termed hub genes, within the network were then identified and further validated in vivo. Network analysis and RT-qPCR revealed that septic hearts treated with MSCs resulted in upregulation of five miRNAs, including miR-187, and decrease in three top hit putative hub genes (Itpkc, Lrrc59, and Tbl1xr1). Functionally, MSC administration decreased inflammatory and apoptotic pathways, while increasing cardiac-specific structural and functional, gene expression. Taken together, our data suggest that MSC administration regulates host-derived miRNAs production to protect cardiomyocytes from sepsis-induced MD.
Insights
Mesenchymal stem/stromal cell (MSC) therapy shows promise for sepsis-induced myocardial dysfunction. MSCs regulate microRNAs (miRNAs) in the heart, decreasing harmful genes and inflammatory pathways to protect heart cells.
Area of Science:
- Cardiology
- Regenerative Medicine
- Molecular Biology
Background:
- Sepsis-induced myocardial dysfunction (MD) is a critical complication of sepsis, contributing to multiorgan failure.
- Current management of MD lacks a deep understanding of its molecular underpinnings.
- Mesenchymal stem/stromal cells (MSCs) are emerging as a potential therapy for sepsis.
Purpose of the Study:
- To investigate the impact of MSC administration on microRNA (miRNA) expression in the heart during sepsis.
- To identify specific miRNAs and their target genes regulated by MSCs in septic hearts.
- To elucidate the molecular mechanisms by which MSCs protect against sepsis-induced MD.
Main Methods:
- Mice underwent polymicrobial sepsis induction (cecal ligation and puncture) and were treated with MSCs or placebo.
- Transcriptomic and microRNA profiling of heart tissue was performed 28 hours post-intervention.
- A putative mRNA-miRNA interaction network was constructed, and key hub genes were identified and validated.
Main Results:
- MSC treatment in septic mice led to the upregulation of five miRNAs, including miR-187.
- Three key hub genes (Itpkc, Lrrc59, Tbl1xr1) were found to be downregulated by MSC administration.
- MSC therapy reduced inflammatory and apoptotic pathways while enhancing cardiac-specific gene expression.
Conclusions:
- MSC administration effectively modulates host-derived miRNA expression in the heart during sepsis.
- This miRNA regulation contributes to the protective effects of MSCs against myocardial dysfunction.
- MSC therapy offers a promising strategy for mitigating sepsis-induced cardiac injury by targeting specific molecular pathways.

